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T-cells are known to be intimately involved in the pathogenesis of multiple sclerosis 
(MS) and its animal model experimental autoimmune encephalomyelitis (EAE). T-cell 
activation is controlled by a range of intracellular signaling pathways regulating cel-
lular responses such as proliferation, cytokine production, integrin expression, and 
migration. These processes are crucial for the T-cells’ ability to mediate inflammatory 
processes in autoimmune diseases such as MS. RhoA is a ubiquitously expressed 
small GTPase well described as a regulator of the actin cytoskeleton. It is essential for 
embryonic development and together with other Rho GTPases controls various cellular 
processes such as cell development, shaping, proliferation, and locomotion. However, 
the specific contribution of RhoA to these processes in T-cells in general, and in auto-
reactive T-cells in particular, has not been fully characterized. Using mice with a T-cell 
specific deletion of the RhoA gene (RhoAfl/flLckCre+), we investigated the role of RhoA 
in T-cell development, functionality, and encephalitogenic potential in EAE. We show 
that lack of RhoA specifically in T-cells results in reduced numbers of mature T-cells 
in thymus and spleen but normal counts in peripheral blood. EAE induction in RhoAfl/fl 
LckCre+ mice results in significantly reduced disease incidence and severity, which 
coincides with a reduced CNS T-cell infiltration. Besides presenting reduced migratory 
capacity, both naïve and autoreactive effector T-cells from RhoAfl/flLckCre+ mice show 
decreased viability, proliferative capacity, and an activation profile associated with 
reduced production of Th1 pro-inflammatory cytokines. Our study demonstrates that 
RhoA is a central regulator of several archetypical T-cell responses, and furthermore 
points toward RhoA as a new potential therapeutic target in diseases such as MS, 
where T-cell activity plays a central role.
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inTrODUcTiOn
Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system (CNS) 
that leads to demyelination and neurodegeneration of gray and white matter (1–3). It is widely 
established that T-cells play an important role in the pathogenesis of MS (2, 4, 5). Both MS and its 
animal model, experimental autoimmune encephalomyelitis (EAE), are suggested to be mediated 
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by Th1 and Th17 cells and share essential pathological and clini-
cal features with MS such as multifocal lymphocytic infiltrations, 
CNS inflammation, demyelination, and axon degeneration, 
which lead to paralysis and sensory disturbances (1, 6).
Therapies targeting immune cells have proven effective in 
MS patients. Antibody therapy with Natalizumab is the second-
line treatment for MS after interferon-β (IFN-β) and Glatiramer 
acetate (7, 8). It targets the α4β1 integrin of lymphocytes, thereby 
inhibiting their migration across the blood–brain barrier 
(BBB) (9–11). Depletion of lymphocytes after treatment with 
the anti-CD52 antibody Alemtuzumab dramatically reduced 
lymphocyte numbers in peripheral blood in RRMS patients, 
thereby stopping the inflammatory and autoimmune process 
from causing further CNS damage, resulting in decreased 
relapse rates (12, 13). This indicates that indeed the prevention 
of immune cell infiltration is a promising therapeutic strategy 
for neuroinflammatory diseases such as MS.
T-cell infiltration into the CNS is a tightly regulated multistep 
process. T-cells migrate from the blood circulation through the 
CNS barriers into the CNS, where T-cells secrete chemokines and 
pro-inflammatory cytokines that trigger BBB breakdown and 
facilitate further T-cell infiltration (3).
Cell migration is dependent on cytoskeletal rearrangements, 
which are in turn regulated by small Rho GTPases (14). To the 
best of our knowledge, the role of T-cell-specific RhoA has 
not been addressed in the context of EAE. More specifically, 
no T-cell conditional knock-out mice for RhoA have been 
studied to investigate if RhoA is essential for transmigration 
of pathogenic T cells via BBB to induce neuroinflammation in 
models of MS. However, several studies have been conducted 
using various in vitro systems. For example, a siRNA screen of 
all Rho GTPases identified RhoA as the main player in T-cell 
transendothelial migration in vitro (15), and experiments using 
the exoenzyme C3 transferase, which inhibits the GTPases 
RhoA, RhoB, and RhoC, also demonstrated the importance of 
these Rho GTPases in monocyte transendothelial migration 
in  vitro (16). It has also been shown that inhibition of Rho 
signaling with C3 transferase results in reduced thymic cel-
lularity, reduced numbers of mature single positive (SP) T-cells 
in the periphery and impaired T-cell clonal expansion in mice 
(17–19). These observations are tightly linked to the important 
role of Rho GTPases in cell migration, as T-cell maturation is 
regulated as they migrates through the thymus (20), and this 
migration in turn has been shown to be dependent on RhoA 
and its downstream effector ROCK (21, 22). Of note, inhibition 
of ROCK has shown beneficial effects in EAE (23), underscor-
ing the therapeutic potential of RhoA for MS treatment and 
stressing the need for further research on the biological role of 
RhoA in T-cells during neuroinflammation.
These studies indicate that RhoA is important for T-cell 
activation and migration. However, the direct impact of RhoA 
on T-cell activation and transmigration from blood into CNS, 
resulting in CNS inflammation, has not been explored in vivo. 
In this study, we investigated whether specifically knocking 
out the small GTPase RhoA in T-cells had an impact on T-cell 
activation and functionality in EAE mice. We show that the 
lack of RhoA expression in T-cells results in a reduction in EAE 
incidence and a significant amelioration of disease severity, 
which coincides with a reduced RhoA−/− T-cell infiltration into 
the CNS. Further characterization suggests that this could be 
due to decreased activation and attenuated encephalitogenic 
profile of RhoA−/− T-cells, shown by a decreased T-cell proli-
feration and cytokine production. Furthermore, RhoA−/− T-cells 
present a significantly impaired transendothelial migratory 
capacity. Taken together, our results suggest that RhoA is 
central for T cell proliferation and activation as well as their 
trans-BBB migratory capacity, and therefore could serve as a 




To generate mice with a T-cell-restricted deletion of the RhoA 
gene (RhoAfl/flLckCre+), RhoAfl/fl (24) and LckCre+v (25) mice 
were crossed. Mice were kept as 129Sv/C57Bl/6 outbred strains. 
RhoAfl/flLckCre−, RhoAfl/+LckCre+, and RhoAfl/flLckCre+ mice 
were bred and housed in the AAALAC certified animal facility 
at the Biotech Research and Innovation Center, University of 
Copenhagen. Mice were housed two to six animals per IVC 
cage with free access to food and water on a 12-h light/dark 
cycle. All procedures were approved and performed in accord-
ance with the Danish Animal Experimentation Committee 
(#2012-DY-2934-00001) and the European Council Directive 
#86/609 for the Care of Laboratory Animals.
induction and evaluation of eae
Experimental autoimmune encephalomyelitis was induced 
in 9- to 16-week-old female mice (RhoAfl/flLckCre− n  =  39, 
RhoAfl/+LckCre+ n = 14, and RhoAfl/flLckCre+ n = 12) by active 
immunization with MOG35–55 following the manufacturer’s 
protocol (Hooke labs, Lawrence, KS, USA). Age-matched mice 
were used in all experiments. Briefly, mice were injected sub-
cutaneously (s.c.) in the upper and lower back with 200 µg of 
MOG35–55 emulsified in complete Freund’s adjuvant, followed by 
the intraperitoneal administration of 100 µl of 4 µg/ml pertussis 
toxin at 2 and 24 h post-immunization. Mice were monitored 
daily for clinical signs of disease and assigned a disease score 
according to the EAE clinical scoring system (0: no clini cal 
symptoms to 5: moribund or dead) devised by the Danish 
Animal Experiments Inspectorate. When animals reached a 
score 3, food and water-gel was provided at the bottom of the 
cage. If animals reached a score 4 or above, or if weight loss 
exceeded 20%, the animals were euthanized. To allow statistical 
evaluation of all animals, accounting also for those that never 
developed disease throughout the experimental period, the day 
of disease debut of mice that never developed EAE was con-
sidered as 1 day after the sacrifice date, i.e., days 42, 43, and 50 
post-immunization. Relapses were defined as an increase of the 
clinical score after the acute phase of disease by at least one point 
on the scoring scale (remission phase), followed by a worsening 
of disease of a minimum of one point on the scoring scale, as 
described previously (26).
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Tissue Preparation
Mice were sacrificed at different stages of the EAE disease course. 
At the end of the experiment, EAE mice were anesthetized with 
5% isoflurane (Forene, Abbot Scandinavia, Stockholm, Sweden) 
delivered in pure oxygen and perfused transcardially with 
phosphate-buffered saline (PBS) until blood was cleared from 
circulation. Brains were collected and snap-frozen in isopentane, 
kept on dry ice, and embedded in Tissue-Tek® (Sakura Finetek 
Denmark ApS, Vaerløse, Denmark). Using a cryostat, 3-µm 
sagittal sections of tissue were collected from four different levels 
with 400-µm distance in between. Sections were mounted on 
superfrost plus slides (Thermo Fisher Scientific, MA, USA) for 
histological or immunohistochemical staining.
For the in  vitro functional assays of naïve T-cells, splenic 
CD3+ T-cells were isolated using a MACS Pan T-cell isolation 
kit II mouse (Miltenyi Biotec, Bergisch Gladbach, Germany). 
T-cells were cultured in complete culture medium composed by 
RPMI 1640 (Thermo Fisher Scientific), 10% FCS supplemented 
with IL-2 (5 ng/ml), and stimulated with plate-bound anti-CD3 
and soluble anti-CD28 at the concentration and time specified 
in each assay.
For the in vitro functional assays of effector/memory T-cells, 
RhoAfl/flLckCre− and RhoAfl/flLckCre+ mice were immunized with 
MOG35–55 following the manufacturer’s protocol (Hooke labs, 
Lawrence, KS, USA) as described above. 11  days after immu-
nization, mice were anesthetized with 5% isoflurane (Forene) 
delivered in pure oxygen and perfused transcardially with PBS 
until blood was cleared from circulation. Spleens were collected 
and single-cell suspensions were prepared by mechanical disrup-
tion through 40-µm cell strainers. Splenocytes were cultured 
in complete culture media composed by RPMI 1640 (Thermo 
Fisher Scientific), 10% FCS supplemented with IL-2 (5 ng/ml), 
and 0.01% 2-Mercaptoetanol (Sigma-Aldrich) and stimulated 
with MOG35–55 (50 µg/ml) for 24–72 h, depending on the assay.
immunohistochemistry
Four brain sections covering the brain from the midline to the 
inner layers of the cortex were randomly chosen for CD3 stain-
ing. Briefly, sections were fixed in acetone at −18°C, rinsed in 
PBS containing 0.05% Tween-20 (PBS-T) (Gibco, Thermo Fisher 
Scientific), and subsequently blocked with PBS-T containing 
5% goat serum (DAKO, Glostrup, Denmark) for 30  min at 
room temperature (RT). The sections were incubated for 1 h at 
RT with monoclonal rabbit anti-mouse CD3 antibody (1:100, 
Abcam clone SP7, Cambridge, UK). The sections were rinsed in 
PBS-T and incubated for 1 h at RT with horseradish peroxidase-
conjugated polyclonal goat anti-rabbit IgG secondary antibody 
(1:400, Abcam). Then sections were rinsed with PBS-T and 
incubated with diaminobenzidine for 30 s. Sections were rinsed 
again in PBS-T before counterstaining with hematoxylin for 20 s 
and dehydration through increasing concentrations of ethanol 
(70, 96, and 99%) and xylene. Sections were mounted with DPX 
mounting media (Cellpath, Newtown, UK).
T-cell Quantification
The stained sections were scanned using a NanoZoomer-2.0HT 
(Hamamatsu, Japan) at 40× magnification, and the micrographs 
were used for quantification of CD3+ cells. The cells were 
manu ally counted in the following areas: cerebral parenchyma, 
meninges, ventricular system, and perivascular space (PVS). The 
anatomical regions were identified using the hematoxylin stain-
ing. All sections were quantified by two blinded observers using 
the QuPath open source software for digital pathology image 
analysis (https://qupath.github.io/) (27).
Flow cytometric analysis of spinal  
cords of eae Mice
Mice at the chronic phase of the EAE disease (36–56 days post-
immunization) were sacrificed, spinal cords were collected, and 
single-cell suspensions were prepared by mechanical disruption 
through 40-µm cell strainers. Single-cell suspensions were stored 
in DMEM medium (Thermo Fisher Scientific) supplemented 
with 10% FCS and 10% DMSO at −80°C until used. Cell suspen-
sions were quickly thawed at 37°C, myelin was removed using 
a MACS Myelin Removal Beads II (Miltenyi Biotec), and cells 
were stained for flow cytometry. Briefly, 5 ×  105 cells in 50  µl 
of cell staining buffer (BioLegend, San Diego, CA, USA) were 
incubated with the viability marker Zombie UV™ (BioLegend) 
for 20 min at RT. Cells were subsequently washed, resuspended 
in 50 µl of cell staining buffer, stained with American hamster 
anti-mouse TCR AF700 (1  μl/test, BioLegend clone H57-597) 
and rat anti-mouse CD4-PE-Cy5 (0.3 µl/ml, eBioscience, clone 
GK1.5) or isotype controls for 30  min on ice. Cells were then 
washed, resuspended in fixation/permeabilization working 
solution (eBioscience), and incubated for 30  min at RT. After 
washing, cells were resuspended in 50 µl cell staining buffer and 
stained with rat anti-mouse IL-4 PE (2 μl/test, BD Biosciences, 
clone 11B11), rat anti-mouse IL-17A FITC (1 μl/test, eBiosci-
ence clone eBio17B7), rat anti-mouse TNFα APC (2 μl/test, BD 
Biosciences clone MP6-XT22), rat anti-mouse IFNγ PE (2 μl/test, 
BD Biosciences clone XMG1.2), rat anti-mouse GM-CSF FITC 
(5  μl/test, eBioscience clone MP1-22E9), and rat anti-mouse 
CD11b FITC (1 μl/test, BD Biosciences clone M1/70) for 30 min 
on ice. Subsequently, cells were washed, resuspended in 400 µl 
of cell staining buffer, and analyzed by flow cytometry. Flow 
cytometry was performed using the LSRII (BD Biosciences) and 
the CellQuest software (BD Biosciences). Data analysis was done 
using the FlowJo V10 software (Tree Star). Isotype controls 
were included as negative controls and subtracted.
Proliferation assay
Spleens were isolated from naïve RhoAfl/flLckCre− and RhoAfl/fl 
LckCre+ mice, and single-cell suspensions were prepared by 
mechanical disruption through 40-µm cell strainers. Naïve 
CD3+ cells were enriched by magnetic cell sorting as described 
above and labeled with Green Cell Trace™ CFSE (Thermo Fisher 
Scientific), 0.5  µM for 107 cells. Labeled cells were cultured 
in 96-well plates (106  cells/ml, Corning Costar, Tewksbury, 
MA, USA) and stimulated with plate-bound anti-mouse CD3 
(5  µg/ml, BioLegend clone 145-2C11) and soluble anti-mouse 
CD28 (2  µg/ml, BioLegend clone 37.51) for 72  h in culture. 
Subsequently, cells were stained with the viability marker 
7-AAD (BioLegend) and analyzed by flow cytometry with the 
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FACS Calibur (BD Bioscience). Data analysis was done using the 
FlowJo V10 software (Tree Star).
For the analysis of proliferation of effector/memory T-cells, 
spleens were isolated from RhoAfl/flLckCre− and RhoAfl/flLckCre+ 
mice immunized with MOG35–55 11 days earlier, and single-cell 
suspensions were prepared as described above. CFSE-labeled 
splenocytes were re-stimulated with MOG35–55 (50 µg/ml, Sigma-
Aldrich) for 48  h in culture, and proliferation was analyzed as 
described above.
cell Viability analysis
The Vybrant™ FAM Caspase-3 and -7 Assay Kit (Life Technologies, 
Thermo Fisher Scientific) was used to evaluate cell viability by 
simultaneously analyzing caspase activity and cell membrane 
permeability by flow cytometry. Naïve CD3+ enriched T-cells 
were isolated as described above and stimulated for 24  h with 
plate-bound anti-mouse CD3 (3 µg/ml, BioLegend) and soluble 
anti-mouse CD28 (3 µg/ml, BioLegend). Effector/memory T-cells 
were isolated from previously MOG35–55-immunized mice as 
described above and stimulated with MOG35–55 (50 µg/ml, Sigma-
Aldrich). Cells were then stained following the manufacturer’s 
protocol. Briefly, 300 µl of cell suspension at a concentration of 
106  cells/ml were incubated with FLICA 30× working solution 
during 1 h at 37°C in the dark. Subsequently, cells were washed 
and incubated on ice with 2 µl of PI for at least 5 min before flow 
cytometric analysis on the LSRII (BD Biosciences). Data analysis 
was done using the FlowJo V10 software (Tree Star).
Determination of T-cell activation state
Briefly, 5 × 105 cells in 50 µl of cell staining buffer (BioLegend) 
were incubated with rat anti-mouse CD4-PE (0.2  µg/test, BD 
Pharmingen clone GK1.5) and rat anti-mouse CD25-PE/Cy5 
(0.125 µg/test, eBioscience clone PC61.5) or isotype controls for 
30 min on ice. Subsequently, cells were washed, resuspended in 
300  µl of cell staining buffer, stained with the viability marker 
7-AAD (BioLegend), and analyzed by flow cytometry. Flow cyto-
metry was performed using the FACS Calibur (BD Biosciences) 
and the CellQuest software (BD Biosciences). Data analysis was 
done using the FlowJo V10 software (Tree Star). Isotype controls 
were included as negative controls and subtracted.
Determination of cytokine  
Production In Vitro
Culture supernatant from RhoA+/+ and RhoA−/− CD3+ T-cells 
was collected after 24, 48, and 72  h of stimulation with plate-
bound anti-mouse CD3 (3 µg/ml, BioLegend) and soluble anti-
mouse CD28 (3 µg/ml, BioLegend) in case of naïve T-cells, or 
with MOG35–55 (50 µg/ml, Sigma-Aldrich) for effector/memory 
T-cells isolated from mice immunized with MOG35–55 11  days 
before. We used the Essential Th1/Th2 Cytokine 6-plex Mouse 
ProcartaPlex™ Panel (Invitrogen, Thermo Fisher Scientific), 
which targets the mouse cytokines IFN-γ, IL-12p70, IL-6, 
TNF-α, IL-4, and IL-5. For the determination of IL-17A, the 
Mouse IL-17A uncoated ELISA kit (Invitrogen) was used. 
Each sample was processed according to the manufacturer’s 
instructions. Samples were analyzed in duplicates, and cytokine 
concentrations were interpolated from the standard curve. The 
multiplex plate was read in the Bio-Plex® MAGPIX™ Multiplex 
reader (BioRad, Hercules, CA, USA) and data acquired using 
the Bio-Plex Manager Software v6.1. The ELISA plate was read 
in the GloMax®-Multi Microplate Multimode Reader (Promega, 
Madison, WI, USA).
Transmigration assay
The T-cell transmigration assay was performed in polycarbon-
ate Transwell™ filter inserts of 8-µm pore size (Corning Costar) 
covered with a confluent monolayer of mouse brain endothelial 
bEnd.3 cells. bEnd.3 cells (passage number > 30) from conflu-
ent 10 cm2 dishes (Corning Costar) were trypsinized and plated 
onto the Transwell™ filter inserts at a seeding density between 
5 × 104 and 105 cells/cm2 in 100 µl of DMEM medium (Thermo 
Fisher Scientific) supplemented with 10% FCS, penicillin G 
(100  U/ml), and streptomycin (100  µg/ml). Culture medium 
was changed every 48–72 h. Splenocytes were CD3+ enriched 
by magnetic sorting as described above and activated with plate-
bound anti-CD3 (3 µg/ml, BioLegend) and anti-CD28 (3 µg/ml, 
BioLegend) for 24  h. When bEnd.3 cells were confluent after 
5  days of culture, the culture medium was removed and 
100 µl of activated T-cells (5 × 104 T-cells/well) in serum-free 
1640 RPMI medium were placed in the upper chamber, and 
600 µl of fresh serum-free 1640 RPMI medium was added in 
the bottom chamber of the Transwell™. The plates were then 
incubated at 37°C in 5% CO2 in the IncuCyte ZOOM® (Essen 
BioScience, Ann Arbor, MI, USA) for live-cell time lapse imag-
ing of the transmigrated cells. Nine images per well from three 
technical replicates were taken every 30 min for 4 h using a 20× 
objective lens and then analyzed using the IncuCyte™ Basic 
Software. In phase contrast, cell segmentation was achieved 
by applying a mask to exclude cells from background. An area 
filter was applied to exclude objects below 10  µm2. After 4  h, 
the transmigrated T-cells present in the bottom chamber were 
recovered and quantified using the Accuri™ C6 flow cytometer 
(BD Biosciences, San Jose, CA, USA). Data analysis was done 
using the FlowJo V10 software (Tree Star).
statistics
Quantitative data are presented as mean ±  SEM. All analyses 
were performed using Prism 7 (GraphPad Prism software) and 
considered significant at p ≤ 0.05. Differences in the EAE disease 
incidence, disease debut, and EAE clinical score (including 
maximum clinical score and mean score during the acute phase) 
were analyzed using Kruskal–Wallis test with Dunn’s multiple 
comparisons test. One-way ANOVA with Dunnett’s multiple 
comparisons test was used to study the differences in the cumu-
lative EAE clinical score. Unpaired Student’s t-test was used to 
evaluate the differences in CD3+ cells infiltrated in EAE brains. 
To analyze differences in the proliferation index, two-way ANOVA 
with Tukey’s multiple comparisons test was used. Multiple t-test 
corrected for false discovery rate (FDR) with the Benjamini, 
Krieger, and Yekutieli method was used to evaluate differences in 
cell viability (apoptosis and necrosis rates). Differential cytokine 
production analysis was done using two-way ANOVA with 
Sidak’s multiple comparisons test and unpaired Student’s t-test 
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for two-group comparisons. The study of the T-cell activation 
capacity was done using one-way ANOVA with Tukey’s multiple 
comparisons test. Differences in the migratory capacity were ana-
lyzed using two-way ANOVA with Sidak’s multiple comparisons 
test and unpaired Student’s t-test for two-group comparisons.
resUlTs
To study the specific role of RhoA in T-cells, mice with a con-
ditional knock-out of the RhoA gene were generated using the 
Cre-loxP system, as previously reported (28). To knock out RhoA 
specifically in T-cells, Cre recombinase was under the control of 
the lymphocyte-specific Lck promoter. We obtained a knock-
out efficiency of ~85% (Figure S1 in Supplementary Material) 
and observations on weight, behavior, and vitality of healthy 
RhoAfl/flLckCre+ mice did not differ from wild-type littermates 
(RhoAfl/flLckCre− mice).
Flow cytometric analysis of the T-cell pool of naïve RhoAfl/fl 
LckCre−, RhoAfl/+LckCre+, and RhoAfl/flLckCre+ mice showed 
that lack of RhoA in T-cells had no impact on the numbers of 
blood circulating lymphocytes, CD3+ cells, SP CD4+ and CD8+ 
cells, double positive (DP) CD4+CD8+ cells, and double nega-
tive (DN) CD4−CD8− cells (Figures S2B–G in Supplementary 
Material, respectively). In thymus of RhoAfl/flLckCre+ mice, 
we observed reduced numbers of lymphocytes, CD3+ cells, SP 
cells, and DP cells (Figures S2H–L in Supplementary Material, 
respectively), and increased numbers of DN cells (Figure S2M 
in Supplementary Material) compared with RhoAfl/+LckCre+ and 
RhoAfl/flLckCre− mice, suggesting defects in early T-cell develop-
ment. In spleen, lymphocyte populations did not differ between 
mice from different genotypes (Figure S2N in Supplementary 
Material), while CD3+ cells and SP cells (Figures S2O–Q in 
Supplementary Material, respectively) were found significantly 
reduced in RhoAfl/flLckCre+ mice compared with RhoAfl/+LckCre+ 
and RhoAfl/flLckCre− mice, suggesting that other lymphocytes 
such as B-cells and NK cells compensated for the lack of T-cells 
in spleen.
These results suggest that RhoA is to some degree indispensable 
for T-cell development, even though the peripheral blood T-cell 
pool was unaffected. Thus, we wondered whether lack of RhoA 
also impacts archetypical T-cell responses such as proliferation, 
cytokine production, and migration, in an autoimmune setting.
lack of rhoa expression in T-cells 
Decreases eae Disease severity
At first, we wanted to determine whether lack of RhoA expression 
in T-cells would affect disease initiation and/or severity of EAE. 
We induced chronic demyelinating EAE in 129Sv/C57Bl/6 mice 
by injection of emulsified myelin oligodendrocyte glyco pro tein 
(MOG35–55). We observed a significantly decreased disease inci-
dence in RhoAfl/flLckCre+ mice compared with its heterozygote 
and homozygote wild-type littermates, RhoAfl/−LckCre+ and 
RhoAfl/flLckCre− mice, respectively (Figure 1A). Furthermore, 
among the RhoAfl/flLckCre+ mice that developed EAE (75%), 
day of disease debut was significantly delayed by 15–30 days 
in these mice compared with RhoAfl/−LckCre+ and RhoAfl/fl 
LckCre− mice (Figure 1B). EAE in RhoAfl/flLckCre+ mice was 
characterized by a lower clinical score and relapse-remission 
frequency compared with RhoAfl/−LckCre+ or RhoAfl/flLckCre− 
mice (Figure 1C; Figures S3A–C and Table S1 in Supplementary 
Material). Moreover, the cumulative EAE score, i.e., overall EAE 
disease severity from day of disease debut until day 37, showed 
significantly less disease activity in the RhoAfl/flLckCre+ mice 
(Figure 1D). In addition, maximum EAE score (Figure 1E) and 
mean EAE score in the acute phase (Figure  1F) also showed 
significantly less disease severity in the RhoAfl/flLckCre+ mice. 
No significant differences were observed in the EAE disease 
severity between RhoAfl/flLckCre− and RhoAfl/−LckCre+ mice. 
These results strongly suggest that the lack of RhoA significantly 
reduces the capacity of T-cells to induce EAE and sustain 
disease severity.
lack of rhoa expression halts T-cell 
infiltration in Brain Parenchyma
Given the less severe EAE disease pattern observed in the RhoAfl/fl 
LckCre+ mice, we next wanted to investigate whether lack of 
RhoA affected the T-cells’ ability to enter the CNS and induce 
disease. We chose to exclude RhoAfl/+LckCre+ mice in all subse-
quent analyses as the EAE disease pattern in those mice did not 
differ significantly from RhoAfl/flLckCre− mice.
We first quantified the number of CD3+ T-cells present in four 
brain sections per mouse of each genotype in the cerebral paren-
chyma, PVS as well as meninges and ventricular system (from 
here on referred to as meninges/ventricles) (Figures  2A–C). 
We observed no significant differences in the number of CD3+ 
T-cells present in the whole brain of RhoAfl/flLckCre− and 
RhoAfl/flLckCre+ mice (Figure S4A in Supplementary Material). 
However, investigating the capacity of T-cells to migrate 
through parenchyma, RhoAfl/flLckCre+ mice presented signifi-
cantly less CD3+ T-cells in the cerebral parenchyma compared 
with RhoAfl/flLckCre− mice (Figure  2D). To examine whether 
RhoA−/− T-cells were trapped in the meninges/ventricles or 
in the PVS, we quantified the CD3+ T-cells present in these 
regions. We did not detect significant differences in the number 
of CD3+ T-cells in these regions between RhoAfl/flLckCre− and 
RhoAfl/flLckCre+ mice (Figures S4B,C in Supplementary 
Material).
Immune cell infiltration in spinal cord highly correlates 
with EAE pathogenesis, thus we analyzed infiltrating cells 
and cytokine production in spinal cords of RhoAfl/flLckCre+ 
and RhoAfl/flLckCre− mice by flow cytometry. Similar to the 
immunohistochemical count of total brain CD3+ cells (Figure 
S4A in Supplementary Material), the analysis revealed no dif-
ferences in the total spinal cord infiltrating lymphocytes (Figure 
S4D in Supplementary Material). However, RhoAfl/flLckCre+ 
mice presented significantly reduced numbers of CD4+ cells in 
spinal cord compared with RhoAfl/flLckCre− mice (Figure 2E). 
Furthermore, CNS infiltrated T-cells in RhoAfl/flLckCre+ mice 
produced reduced amounts of the pro-inflammatory cytokines 
IFNγ (Figure 2F), TNFα (Figure 2G), and GM-CSF (Figure 2H), 
although not statistically significant. Surprisingly, we found sig-
nificantly elevated levels of the Th17 cytokine IL-17A (Figure 2I) 
FigUre 1 | Lack of RhoA in T-cells reduces experimental autoimmune encephalomyelitis (EAE) disease incidence, onset and severity. (a) Disease incidence in 
RhoAfl/flLckCre−, RhoAfl/+LckCre+, and RhoAfl/flLckCre+ mice. (B) Day of disease debut of mice from the three different genotypes. (c) EAE disease profile after 
disease onset in RhoAfl/flLckCre−, RhoAfl/+LckCre+, and RhoAfl/flLckCre+ mice. (D) Overall EAE disease severity in the three different genotypes, represented as the 
cumulative EAE score over the entire study period. (e) Maximum disease score reached by each mouse throughout the experiment. (F) Mean disease score of each 
mouse during the acute phase of the disease (days 1–9 after disease debut). RhoAfl/flLckCre− n = 39, RhoAfl/+LckCre+ n = 13, RhoAfl/flLckCre+ n = 12. Data shown 
as mean ± SEM. *p < 0.05, **p < 0.01 (Kruskal–Wallis test followed by Dunn’s test).
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and the Th2 cytokine IL-4 (Figure 2J) in these cells. Presence 
of infiltrating CD11b+ macrophages was also reduced in spinal 
cords of RhoAfl/flLckCre+ mice compared with RhoAfl/flLckCre− 
mice (Figure  2K). These results indicate that lack of RhoA 
compromises T-cell’s ability to infiltrate the CNS and mount a 
Th1 pro-inflammatory response. The reduction of infiltrating 
macrophages in RhoAfl/flLckCre+ mice is probably a consequence 
of the reduced pro-inflammatory profile of T-cells, which results 
in reduced BBB breakdown, reduced immune cell infiltration, 
and reduced APC activation.
lack of rhoa Prevents MOg-specific 
effector T-cell responses
Although in support of lower EAE disease, we found less CD3+ 
T-cells in the cerebral parenchyma and less CD4+ T-cells in spinal 
cord of RhoAfl/flLckCre+ mice compared with RhoAfl/flLckCre− 
mice, the unexpected findings that the number of CD3+ T-cells 
were similar in the meninges, ventricular system, and PVSs 
could be an indication that RhoA might play an essential role in 
antigen-specific T-cell activation, proliferation, and/or cytokine 
production in addition to T-cell migration. To address the role of 
FigUre 2 | Continued
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FigUre 2 | Lack of RhoA expression prevents T-cell infiltration in brain parenchyma. (a) Representative micrograph of a sagittal brain section from a RhoAfl/fl 
LckCre− mouse, stained for CD3. Magnification of the brain section from a RhoAfl/flLckCre− mouse (B) and a RhoAfl/flLckCre+ mouse (c), where CD3+ T-cells can  
be observed in the brain parenchyma (black arrows) and the perivascular space (red arrows). (D) Quantification by IHC of the CD3+ T-cells present in the cerebral 
area of the brain section from RhoAfl/flLckCre− (n = 33) and RhoAfl/flLckCre+ (n = 24) brain sections. Data are represented as number of CD3+ T-cells per area (mm2).  
(e–K) Quantification by flow cytometry of CD4+ T-cells (e), IFNγ+ T-cells (F), TNFα+ T-cells (g), GM-CSF+ T-cells (h), IL-17A+ T-cells (i), IL-4+ T-cells (J), and  
CD11b+ cells (K) present in spinal cord of experimental autoimmune encephalomyelitis mice (n = 3 per group). Data shown as mean ± SEM. *p < 0.05,  
**p < 0.01 (unpaired t-test).
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RhoA in T-cell activation, we investigated whether the decreased 
disease activity in RhoAfl/flLckCre+ mice could be due to defects 
in antigen-specific, MOG35–55 T-cell responses.
We investigated the proliferative capacity of T-cells in res-
ponse to MOG35–55 by studying T-cells purified from MOG35–55- 
immunized RhoAfl/flLckCre− compared with RhoAfl/flLckCre+ 
mice, i.e., RhoA+/+ and RhoA−/− T-cells, based on CFSE labe-
ling and flow cytometric detection. Lack of RhoA expression 
significantly compromised the T-cell’s ability to proliferate in 
response to the antigen-specific stimulation (Figures  3A,B). 
Interestingly, further analysis revealed that poor MOG35–55 
response in RhoA−/− T-cells is associated with lack of survival, 
as MOG35–55 activation of RhoA−/− T-cells results in significantly 
elevated rates of apoptosis (Figures  3C,D). These results 
indicate that MOG35–55 immunization of mice generates a poor 
immune response when T-cells lack RhoA compared with RhoA 
competent T-cells.
Next, it was of interest to analyze if poor ability of RhoA−/− 
T-cells to proliferate in response to MOG35–55 could also impact 
their cytokine profile, which is closely associated with antigen-
specific T-cell capacity to induce EAE (1, 6). We therefore quan-
tified an array of Th1/Th2/Th17 prototype cytokines produced 
in the culture supernatant of RhoA+/+ and RhoA−/− T-cells after 
24, 48, and 72 h of stimulation with MOG35–55. RhoA−/− T-cells 
produced significantly less Th1 pro-inflammatory cytokines, 
as evidenced by the low expression of IFN-γ and the complete 
lack of IL-12 production (Figures  3E,F). Production of the 
pro-inflammatory cytokines IL-6 and TNF-α, often associated 
with Th1 responses and disease activity, were also significantly 
reduced in MOG35–55 stimulated RhoA−/− T-cells compared 
with the RhoA+/+ T-cells (Figures  3G,H). Regarding the Th2 
and Th17 cytokines, even though RhoA−/− T-cells can produce 
similar amounts of cytokines after 72 h of MOG35–55 stimula-
tion, their production is reduced in early time points, which 
is significantly pronounced in the case of IL-5 and IL-17A 
(Figures 3I–K).
Taken together, these results indicate that lack of RhoA sig-
nificantly compromises the T-cells’ ability to respond to their 
cognate antigen and are thereby defective in inducing EAE.
rhoa is important for antigen-
independent T-cell responses
After firmly having established that effector T-cells isolated from 
MOG-immunized RhoAfl/flLckCre+ mice are unable to mount a 
proper recall antigen response, we wanted to test whether this 
was unique to effector RhoA−/− T-cell responses, or whether naïve 
RhoA−/− T-cells would exhibit the same defects when activated 
with anti-CD3/anti-CD28 antibodies.
Similar to what we observed in the effector T-cell popula-
tion, RhoA−/− T-cells presented a significantly lower prolifera-
tive capacity compared with RhoA+/+ T-cells (Figures  4A,B). 
By quan tifying the surface levels of the activation marker CD25 
of splenic CD4+ T-cells isolated from RhoAfl/flLckCre− and 
RhoAfl/flLckCre+ mice (Figure 4C), we observed that RhoA−/− 
T-cells reach a significantly lower (~60% less) activation state 
compared with RhoA+/+ T-cells in response to activation with 
anti-CD3/anti-CD28 antibodies (Figure 4D).
When studying the viability of RhoA+/+ and RhoA−/− T-cells, 
based on their labeling intensity of PI and FLICA (Figure 4E), we 
observed no differences in the frequency of apoptotic, necrotic, 
or alive RhoA−/− T-cells compared with RhoA+/+ T-cells, although 
RhoA−/− T-cells showed a tendency toward more apoptosis 
(Figure 4F). This resembles the higher apoptosis rate observed in 
MOG35–55-specific effector/memory RhoA−/− T-cells (Figure 3D).
Upon anti-CD3/anti-CD28 stimulation, similar to MOG35–55- 
specific stimulation, the cytokine production of T-cells was 
significantly decreased in the absence of RhoA. RhoA−/− T-cells 
present a tendency to a lower production of the classical Th1 
cytokine IFN-γ (Figure  4G) and a significantly reduced pro-
duction of the pro-inflammatory Th1-associated cytokines IL-6 
and TNF-α (Figures 4H,I). In this case, the Th1 cytokine IL-12 
was not detectable in either RhoA+/+ or RhoA−/− T-cells (data 
not shown). We also observed a trend to a reduced production 
of Th2 cytokines IL-4 and IL-5 by RhoA−/− T-cells after 24 h of 
anti-CD3/anti-CD28 stimulation (Figures 4J,K), which resem-
bles our observations at the 24-h time point with MOG35–55-
specific effector/memory T-cells (Figures 3I,J). RhoA−/− T-cells 
also presented a significantly reduced production of the Th17 
cytokine IL-17A (Figure 4L). Taken together, these results sug-
gest that RhoA is important for both the initial activation of 
naïve T-cells and reactivation of effector T-cells.
rhoa expression is crucial for T-cell 
Transendothelial Migration
It is well established that RhoA is a main regulator of cellular 
migration (14, 29). We therefore proceeded to investigate if the 
migratory capacity of RhoA−/− T-cells is also compromised, 
which could contribute to the manifested significantly lower 
clinical EAE. We established a confluent layer of bEnd.3 cells to 
mimic BBB and measured ability of T-cells to cross this endothe-
lial cell barrier. As shown in Figure 5A, RhoA−/− T-cells migrate 
significantly slower across the endothelial barrier compared 
with RhoA+/+ T-cells, resulting in ~27% fewer cells after 4 h of 
migration (Figures  5B–D). This indicates that RhoA plays an 
important role in the migratory capacity of T-cells across an 
endothelial barrier like the BBB.
FigUre 3 | Continued
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FigUre 3 | Lack of RhoA halts T-cell immune responses against the encephalitogenic antigen, MOG35–55. (a) Representative histogram of the proliferation  
of RhoA+/+ and RhoA−/− T-cells in vitro based on their CFSE labeling. (B) Quantification of the proliferation index (fold increase in proliferation in relation to 
unstimulated RhoA+/+ T-cells) of RhoA+/+ (filled bars) and RhoA−/− (striped bars) T-cells upon MOG35–55 activation for 48 h. Data represents the mean of two 
independent experiments (RhoA+/+ n = 4, RhoA−/− n = 3). (c) Representative gating strategy for the analysis of cell viability. (D) Quantification of the percentage of 
necrotic (N), apoptotic (EA + LA) and living (L) cells in RhoA+/+ and RhoA−/− T-cells after 24 h of MOG35–55-activation in vitro. (e–K) Quantification of the amount of 
IFN-γ, IL-12p40, IL-6, TNF-α, IL-4, IL-5, and IL-17A present in the supernatant of RhoA+/+ (continuous line) and RhoA−/− (dotted line) T-cells after 24, 48, and 72 h  
in culture in the presence of MOG35–55. Data shown as mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 [(B) One-way ANOVA, followed by Tukey’s 
test. (D) Multiple t-test, followed by FDR correction. (e–J) Multiple t-test, followed by FDR correction]. Abbreviation: FSC, forward scatter; SSC, side scatter; PI, 
propidium iodide; FLICA, fluorescent inhibitor of caspases; L, living; N, necrotic; EA, early apoptotic; LA, late apoptotic; FDR, false discovery rate.
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DiscUssiOn
Although RhoA signaling has been reported to be important for 
T-cell activation in vivo and in various T-cell migration in vitro 
models (14), the direct impact of RhoA on T-cell’s capacity to 
cross BBB and induce disease in the CNS has not been estab-
lished. In this study, using mice with a T-cell-specific RhoA gene 
deletion (RhoAfl/flLckCre+ mice) we show that RhoA is important 
in various aspects of T-cell biology as well as for the T-cell’s ability 
to induce severe EAE.
T-cell infiltration into the CNS is tightly linked to the 
pathogenesis of EAE and MS (2, 3, 6, 30). In turn, T-cell migra-
tion is dependent on cytoskeletal rearrangements, which are 
regulated by Rho GTPases (14). Previous studies have shown 
that the treatment of splenic mononuclear cells (MNCs) with 
fasudil, which inhibits the Rho downstream kinase ROCK 
(31, 32), ameliorates the clinical severity of active and adoptive 
EAE and reduces MNCs’ CNS infiltration (23). The researchers 
suggest that fasudil treatment reduces the encephalitogenicity 
of MNCs and induces macrophage polarization from patho-
genic M1 to beneficial M2 macrophages (23). However, ROCK 
inhibition with fasudil inhibits signaling from GTPases other 
than RhoA, i.e., RhoB and RhoC, and treating mice systemi-
cally with fasudil could generally impact ROCK signaling in 
all types of cells expressing ROCK, hence making it difficult to 
address the specific role of RhoA in T-cells only. Here, we show 
for the first time that T-cell specific deletion of RhoA is enough 
to ameliorate EAE severity. Our results show that the lack of 
RhoA in T-cells markedly delays the EAE onset and reduces 
the EAE incidence and clinical severity. The histopathological 
analysis of CNS tissue from EAE mice revealed significantly 
reduced numbers of infiltrating T-cells in the cerebral paren-
chyma and spinal cords of RhoAfl/flLckCre+ mice compared 
with RhoAfl/flLckCre− mice. Furthermore, CNS-infiltrating 
T-cells of RhoAfl/flLckCre+ mice showed reduced production 
of the pro-inflammatory cytokines IFNγ, TNFα, and GM-CSF 
in spinal cord, tightly linked to EAE pathogenesis and disease 
activity. Interestingly, we also observed a significantly reduced 
infiltration of CD11b+ cells in the spinal cord of RhoAfl/flLck-
Cre+ mice, which could be a consequence of lower levels of 
T  cell activation and pro-inflammatory cytokine production 
in the periphery to impact directly APC activation and APC 
recruitment, or indirectly by reduced BBB breakdown and 
hence lower infiltration in the area. These criteria are also 
important reasons behind the ameliorated EAE observed in 
RhoAfl/flLckCre+ mice, given that EAE severity is tightly related 
to the level of T-cell and macrophage infiltrates in the CNS.
The small GTPase RhoA regulates a range of T-cell functions 
including development, activation, cell cycle, proliferation, and 
migration (14, 33, 34). Studies have shown that inhibition of 
Rho signaling with C3 transferase results in reduced thymic cel-
lularity and reduced numbers of mature T-cells in the periphery 
[96, 97, 108]. It has also been demonstrated that Rho signaling 
is present in the immunological synapse and downstream of the 
T-cell receptor (TCR) (35), and RhoA is known to be involved 
in TCR-mediated signal transduction (36). Moreover, T-cells 
expressing a constitutively active RhoA (V14RhoA) have been 
shown to be hyperresponsive in the context of TCR-induced 
proliferation (37), and a study using mice knock-out for TAGAP, 
a T-cell-specific RhoA-activating protein, demonstrated that 
RhoA activation enhances TCR-mediated Th17 differentiation, 
thereby contributing to EAE pathogenesis (38). Consistent 
with these findings, we show that RhoAfl/flLckCre+ mice present 
reduced numbers of mature T-cells in thymus and spleen but 
normal counts in peripheral blood. Furthermore, lack of RhoA 
reduces T-cell activation capacity, increases T-cell apoptosis 
rates, and significantly reduces proliferation of both autoreac-
tive effector/memory T-cells and naïve T-cells. It is known that 
reactivation of T-cells by macrophages in the CNS parenchyma 
is important during CNS invasion and inflammation in MS and 
EAE (39). The impaired activation capacity of RhoA-deficient 
T-cells and the decreased number of macrophages in the CNS 
of RhoAfl/flLckCre+ mice might result in defective T-cell reac-
tivation, further contributing to the decreased EAE severity 
observed in these mice. The reduced T-cell activation capacity of 
RhoA-deficient T-cells is most likely the cause of their reduced 
pro-inflammatory cytokine production. The impaired T-cell 
development together with the reduced activation and prolifera-
tive capacity and the elevated cell death might be underlying 
causes of the reduced numbers of T-cells present in the CNS 
after EAE in RhoAfl/flLckCre+ mice.
Cytokines are important mediators of T-cell function and 
pathogenicity, and they are of interest as therapeutic targets for 
inflammatory diseases like MS (40). Indeed, the immunomodula-
tors IFN-β and Glatiramer acetate, which constitute the first-line 
treatment for MS, downregulate the production of chemokines 
and pro-inflammatory cytokines such as IFN-γ and IL-6 (41, 
42). Supporting pro-inflammatory cytokine-signaling pathways 
as targets of therapy, the anti-IL2Rα antibody Daclizumab has 
been approved for the treatment of RRMS (43), and the blockage 
of the GM-CSF receptor has been shown beneficial in a RR-EAE 
mouse model (44). Antibody therapy with Ustekinumab, which 
targets the cytokines IL-12/23, has been shown to inhibit EAE 
in mice (45), even though it failed to show efficacy in RRMS 
FigUre 4 | Continued
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FigUre 4 | RhoA expression is important for pan T-cell responses. (a) Representative histogram of the proliferation of RhoA+/+ and RhoA−/− T-cells in vitro based  
on their CFSE labeling. (B) Proliferation index of RhoA+/+ (filled bars) and RhoA−/− (striped bars) T-cells upon pan-activation with anti-CD3/CD28 antibodies for 72 h. 
Data represent the mean of two independent experiments, n = 3 mice per group. (c) Representative gating strategy for the analysis of cell activation.  
(D) Quantification of the percentage of CD4+CD25+RhoA+/+ and RhoA−/− T-cells in the presence or absence of pan-activation. Data represent the mean of two 
independent experiments, n = 3 mice per group. (e) Representative gating strategy for the analysis of cell viability. (F) Quantification of the percentage of necrotic 
(N), apoptotic (EA + LA) and living (L) cells in RhoA+/+ and RhoA−/− T-cells after 24 h of pan-activation in vitro. Data represent the mean of three independent 
experiments, n = 4 mice per group. (g–l) Amount of IFN-γ, IL-6, TNF-α, IL-4, IL-5, and IL-17A present in the supernatant of RhoA+/+ and RhoA−/− T-cells after 24 h 
stimulation with anti-CD3/CD28. Data shown as mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 [(B) Two-way ANOVA, followed by Tukey’s test. 
(D) One-way ANOVA, followed by Tukey’s test. (F) Multiple t-test, followed by FDR correction. (g–K) Unpaired t-test]. Abbreviation: FSC, forward scatter; SSC,  
side scatter; PI, propidium iodide; FLICA, fluorescent inhibitor of caspases; L, living; N, necrotic; EA, early apoptotic; LA, late apoptotic; FDR, false discovery rate.
FigUre 5 | RhoA is important in T-cell transendothelial migration. (a) Quantification of migratory capacity of RhoA+/+ and RhoA−/− T-cells across an endothelium, 
analyzed by live-cell time lapse imaging. Data representative of two independent experiments. (B) Representative images of migrated RhoA+/+ (left) and RhoA−/− 
(right) T-cells at the bottom of the migration chamber after 4 h of migration. Marked in orange are the migrated cells detected and quantified by the software 
IncuCyte™ Basic Software (c). Gating strategy used for flow cytometric analysis of migrated T-cells. (D) Quantification of the total number of migrated cells after  
4 h by flow cytometry. Data represent the mean of two independent experiments. Data shown as mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
[(a) Two-way ANOVA, followed by Sidak’s test. (D) Unpaired t-test].
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patients, supposedly due to low CNS availability of the compound 
or to the advanced stage of the RRMS pathology at the time of 
treatment (46). Here, we show that the lack of RhoA reduces the 
pro-inflammatory cytokines’ production by both autoreactive 
effector/memory T-cells and naïve T-cells in  vitro, indicating 
a dampened pathogenic T-cell reactivity in the absence of 
RhoA. Similarly, CNS infiltrated RhoA−/− autoreactive T-cells 
produced reduced amounts of the pro-inflammatory cytokines 
IFNγ, TNFα, and GM-CSF in comparison to RhoA+/+ T-cells. 
Interestingly, and contrarily to our observations in vitro, we found 
significantly more IL-17- and IL-4-producing T-cells in the CNS 
of RhoAfl/flLckCre+ mice compared with RhoAfl/flLckCre− mice. 
The fact that a different and more complex inflammatory milieu 
exists in  vivo could explain these discrepancies. Furthermore, 
this could illustrate a change in the T-cell phenotype as the 
disease progresses, changing from a Th1 phenotype to a Th17 
and Th2 phenotype. In addition, the T-cells were isolated from 
inflamed spinal cords at different stages of disease progression, 
given the significantly later disease debut in the RhoAfl/flLckCre+ 
mice.
Given the key regulatory role of Rho GTPases in cell migra-
tion (47), there has been effort to inhibit Rho GTPases to inhibit 
lymphocyte recruitment to the CNS (48). Our current study 
strongly supports that the lack of RhoA specifically in T-cells 
reduces their migratory capacity and velocity compared with 
RhoA+/+ T-cells, associated with lower incidence and severity 
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